Terms: = Bone cancer AND H3F3A, P84243, H3_3B, MGC87783, MGC87782, H3F3, H3_3A, ENSG00000163041, 3020 AND Treatment
29 results:
1. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone: NCC-GCTB8-C1 and NCC-GCTB9-C1.
Adachi Y; Noguchi R; Yoshimatsu Y; Sin Y; Osaki J; Ono T; Iwata S; Akiyama T; Tsuchiya R; Toda Y; Ishihara S; Ogura K; Kobayashi E; Kojima N; Yoshida A; Yokoo H; Kawai A; Kondo T
Hum Cell; 2024 May; 37(3):874-885. PubMed ID: 38466561
[TBL] [Abstract] [Full Text] [Related]
2. Cycle-generative adversarial network-based bone suppression imaging for highly accurate markerless motion tracking of lung tumors for cyberknife irradiation therapy.
Mochizuki Z; Saito M; Suzuki T; Mochizuki K; Hasegawa J; Nemoto H; Satani K; Takahashi H; Onishi H
J Appl Clin Med Phys; 2024 Jan; 25(1):e14212. PubMed ID: 37985163
[TBL] [Abstract] [Full Text] [Related]
3. Adult granulosa cell tumor of the testis with malignant tendency: A case report with genetic analysis using high-throughput sequencing.
Deng L; Zeng J; Qiu JF; Yang LH; Ma J
Medicine (Baltimore); 2023 Aug; 102(32):e34523. PubMed ID: 37565864
[TBL] [Abstract] [Full Text] [Related]
4. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone.
Ono T; Noguchi R; Yoshimatsu Y; Sin Y; Tsuchiya R; Akiyama T; Kojima N; Toda Y; Sato C; Fukushima S; Yoshida A; Kawai A; Kondo T
Hum Cell; 2023 Sep; 36(5):1804-1812. PubMed ID: 37328637
[TBL] [Abstract] [Full Text] [Related]
5. [Giant cell tumour of bone in the rib cage treated with denosumab. A case report].
Serret Miralles P; Orellana Fernández R; Parra Parente T; García-Chamón Brígido RB; Carrera Salas R
Rev Esp Patol; 2023; 56(2):119-123. PubMed ID: 37061238
[TBL] [Abstract] [Full Text] [Related]
6. Prognosis of patients with unresectable stage IV Colon cancer undergoing primary tumor resection: A multicenter study of minimally symptomatic or asymptomatic primary tumor.
Ho MF; Lai VC; Ng DCK; Ng SSM
Asian J Surg; 2023 Sep; 46(9):3710-3715. PubMed ID: 36522225
[TBL] [Abstract] [Full Text] [Related]
7. Malignant Transformation of Giant Cell Tumour of bone: A Review of Literature and the Experience of a Referral Centre.
Vari S; Riva F; Onesti CE; Cosimati A; Renna D; Biagini R; Baldi J; Zoccali C; Anelli V; Annovazzi A; Covello R; Ascione A; Casini B; Ferraresi V
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142631
[TBL] [Abstract] [Full Text] [Related]
8. The Activation of PDGFRβ on Mononuclear Stromal/Tumor Cells in Giant Cell Tumor of bone After Denosumab treatment. An Immunohistochemical Study of Five Cases.
Antal I; Pápai Z; Szendrői M; Perlaky T; Dezső K; Lippai Z; Sápi Z
Pathol Oncol Res; 2022; 28():1610633. PubMed ID: 36091939
[TBL] [Abstract] [Full Text] [Related]
9. Updated concepts in treatment of giant cell tumor of bone.
van der Heijden L; Lipplaa A; van Langevelde K; Bovée JVMG; van de Sande MAJ; Gelderblom H
Curr Opin Oncol; 2022 Jul; 34(4):371-378. PubMed ID: 35837707
[TBL] [Abstract] [Full Text] [Related]
10. Establishment and characterization of NCC-GCTB5-C1: a novel cell line of giant cell tumor of bone.
Akiyama T; Yoshimatsu Y; Noguchi R; Sin Y; Tsuchiya R; Ono T; Fukushima S; Toda Y; Kojima N; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2022 Sep; 35(5):1621-1629. PubMed ID: 35653034
[TBL] [Abstract] [Full Text] [Related]
11. Diagnostic Utility of Genetic and Immunohistochemical
Wągrodzki M; Tysarowski A; Seliga K; Wojnowska A; Stepaniuk M; Castañeda Wysocka P; Makuła D; Pieńkowski A; Szostakowski B; Zub R; Rutkowski P
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055156
[TBL] [Abstract] [Full Text] [Related]
12. Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases.
Yang L; Zhang H; Zhang X; Tang Y; Wu Z; Wang Y; Huang H; Fu X; Liu J; Hogendoorn PCW; Cheng H
Ann Diagn Pathol; 2022 Apr; 57():151882. PubMed ID: 34995868
[TBL] [Abstract] [Full Text] [Related]
13. Establishment and characterization of the NCC-GCTB4-C1 cell line: a novel patient-derived cell line from giant cell tumor of bone.
Ono T; Noguchi R; Yoshimatsu Y; Tsuchiya R; Sin Y; Nakagawa R; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
Hum Cell; 2022 Jan; 35(1):392-399. PubMed ID: 34731453
[TBL] [Abstract] [Full Text] [Related]
14. Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone.
Yoshimatsu Y; Noguchi R; Tsuchiya R; Ono T; Sin Y; Akane S; Sugaya J; Mori T; Fukushima S; Yoshida A; Kawai A; Kondo T
Hum Cell; 2021 Nov; 34(6):1899-1910. PubMed ID: 34304386
[TBL] [Abstract] [Full Text] [Related]
15. [Intraosseous metastasis of K27-mutant glioma].
Ryzhova MV; Galstyan SA; Starovoitov DV; Snigireva GP; Zubova IV; Golanov AV; Pronin IN; Pavlova GV; Mertsalova MP; Belov AI; Kalinin PL; Serova NK
Arkh Patol; 2021; 83(3):40-44. PubMed ID: 34041895
[TBL] [Abstract] [Full Text] [Related]
16. Current concepts in the treatment of giant cell tumour of bone.
van der Heijden L; Dijkstra S; van de Sande M; Gelderblom H
Curr Opin Oncol; 2020 Jul; 32(4):332-338. PubMed ID: 32541321
[TBL] [Abstract] [Full Text] [Related]
17. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
Yamamoto H; Ishihara S; Toda Y; Oda Y
Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
[TBL] [Abstract] [Full Text] [Related]
18. Denosumab-treated Giant Cell Tumors of bone: A Clinicopathologic Analysis of 35 Cases From the French Group of bone Pathology.
Treffel M; Lardenois E; Larousserie F; Karanian M; Gomez-Brouchet A; Bouvier C; Le Loarer F; Aubert S; de Pinieux G; Audard V; Rios M; Sirveaux F; Vignaud JM; Gauchotte G; Marie B
Am J Surg Pathol; 2020 Jan; 44(1):1-10. PubMed ID: 31651524
[TBL] [Abstract] [Full Text] [Related]
19. Genetic profiling of a chondroblastoma-like osteosarcoma/malignant phosphaturic mesenchymal tumor of bone reveals a homozygous deletion of CDKN2A, intragenic deletion of DMD, and a targetable FN1-FGFR1 gene fusion.
Saba KH; Cornmark L; Rissler M; Fioretos T; Åström K; Haglund F; Rosenberg AE; Brosjö O; Nord KH
Genes Chromosomes Cancer; 2019 Oct; 58(10):731-736. PubMed ID: 31066955
[TBL] [Abstract] [Full Text] [Related]
20. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
Moskowitz CH; Walewski J; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Viviani S; Bachanova V; Sureda A; McClendon T; Lee C; Lisano J; Sweetenham J
Blood; 2018 Dec; 132(25):2639-2642. PubMed ID: 30266774
[TBL] [Abstract] [Full Text] [Related]
[Next]
